RxDoctor Payments Data

Ming Huang, MD

Family Medicine · Somerville, NJNPI 1891897583

Payments from drug & device makers

$1,163in general payments, 2019–2025

Across 44 payments — averaging $26.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$707
  • Amarin Pharma, Inc.$213
  • Merck$176
  • Novo Nordisk$41
  • AbbVie$14
  • Novartis$12

What the payments were for

  • Food & beverage$1,163100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca32$707
Amarin Pharma, Inc.2$213
Merck5$176
Novo Nordisk3$41
AbbVie1$14
Novartis1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,163 in reported general payments places this provider in the 65th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$37,984
Medicare patients
90
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol17$28,298
JanuviaSitagliptin Phosphate11$13,786
AtacandCandesartan Cilexetil14$4,697
Atorvastatin Calcium179$1,302
Metoprolol Succinate75$1,127
Tamsulosin Hcl75$952
Valsartan29$901
Metformin Hcl80$749
Amlodipine Besylate107$736
Rosuvastatin Calcium40$573
Allopurinol43$399
Lisinopril37$365
Levothyroxine Sodium39$316
Losartan Potassium42$272
Pantoprazole Sodium24$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Atacand$707$32,99531 claims
MerckJanuvia$176$13,78611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Somerville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →